The Impact of Outpatient Chemotherapy-Related Adverse Events on the Quality of Life of Breast Cancer Patients

Tachi, Tomoya; Teramachi, Hitomi; Tanaka, Kazuhide; Asano, Shoko; Osawa, Tomohiro; Kawashima, Azusa; Yasuda, Masahiro; Mizui, Toshiyuki; Nakada, Takumi; Noguchi, Yoshihiro; Tsuchiya, Teruo; Goto, Chitoshi

doi:10.1371/journal.pone.0124169

Cited by 59 publications

(61 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were 7 studies covering 2 topics each [3,13,14,15,16,17,18] and 7 meta-analyses [19,20,21,22,23,24,25]. 20 studies (29.4%) were from Europe [3,5,9,10,11,12,15,22,26,27,28,29,30,31,32,33,34,35,36,37,38,] 20 from the US [4,14,17,19,20,24,39,40,41,42,43,44,45,46,47,48,49,50,51,52], 3 studies (4.4%) from US plus Europe [23,53,54], 6 studies (8.8%) from Japan [16,55,56,57,58,59], 6 studies (8.8%) from China [18,25,60,61,62,63], 2 studies (3.0%) from Hong Kong [13,64,65], 3 studies (4.4%) from Canada [66,67,68], 3 studies (4.4%) from India [21,69,70] and 5 studies (7.4%) from other countries [7,71,72,73,74]. 21 studies (30.9%) used the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale for assessment of OM.…”

Section: Resultsmentioning

confidence: 99%

“…1 Studies on oral mucositis (OM). Incidence of OM was investigated in patients with hematopoietic stem cell transplantation (HSCT) in 14 studies (32.6%) [3,5,14,17,19,28,31,36,37,39,44,56,62,67], in head and neck cancer (HNC) patients in 13 studies (30.2%) [18,21,29,40,50,51,55,59,60,61,63,70,73], in patients with chemotherapy in 13 studies (30.2%) [15,16,22,23,24,25,30,34,38,46,48,58,71], with mixed tumor types and treatment in 1 study (2.3%) [13] and with palliative care in 2 studies (4.7%) [32,57]. Cost related to OM in patients undergoing HSCT was the focus in 4 studies [7,14,17,54], in HNC patients in 2 studies [43,47], in patients with chemotherapy in 6 studies [9,10,11,12,42,49,68], and in patients with mixed tumor types and treatment in 2 studies [20,45].…”

Section: Resultsmentioning

confidence: 99%

“…Resource use associated with OM was reported in 3 studies concerning patients with HSCT [3,7,17], 2 studies with HNC [4,43] and 1 study with chemotherapy [42] and 1 study with mixed tumor types and treatment [45]. The impact of OM on health-related quality of life (HRQoL) was investigated in 1 study in patients with HSCT [35], 5 studies with HNC [18,52,53,66,72], 6 studies with chemotherapy [15,16,26,27,41,74], and 4 studies with mixed tumor types and treatment [13,33,64,65,69]. …”

Section: Resultsmentioning

confidence: 99%

“…In patients with chemotherapy for solid tumors, OM frequency for all grades is reported to be between 14.4% and 81.3% depending on the type of tumor and treatment, with a preponderance of mild OM (grade < 3), and a frequency of severe OM (grade ≥ 3) generally below 5% [15,16,24,30,34,38,58]. In a study on patients with advanced cancer, overall prevalence of OM was 22.3% [32].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

et al. 2018

View full text Add to dashboard Cite

Background: Surprisingly little is known about the burden of oral mucositis (OM). We provide a systematic review of studies on the burden of OM (incidence, economic impact, health-related quality of life (HRQoL)). Methods: Systematic literature searches were made in BIOSIS, EMBASE, and MEDLINE. Inclusion criteria were studies on OM in hematology/oncology patients of ≥ 18 years, journal articles, English language, and published between 2000 and 2016; OM treatment studies were excluded. Quality assessment was performed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: We screened 4,996 hits, and identified 68 studies of which 13 were without transparency on OM grading. The evidence level of 65 studies was rated ‘low' or ‘very low' in 58.5%, ‘moderate' in 20% and ‘high' in 21.5%. Mean value of incidence (7 studies) was 83.5% for all grades of OM with hematopoietic stem cell transplantation. OM incidence for all grades in head and neck cancer patients was 59.4-100%. Considering the economic impact, 16 studies showed highly variable numbers. HRQoL was measured in 16 studies using 13 different instruments. Statistically significant changes in HRQoL scores were demonstrated. Conclusion: OM is common, burdensome, costly and imposes major reductions in HRQoL. However, from a quality standpoint, the level of current evidence in OM is disappointing. The field needs continued attention to address methodological challenges.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

et al. 2018

View full text Add to dashboard Cite

show abstract

“…There are a few transitional phases in cancer treatment that directly affect QoL such as 'diagnosis stage', 'adjuvant treatment', 'follow-up' and 'treatment finalization', which are directly associated with a decrease of the QoL, mainly related to concerns and fears [21]. However, some studies have shown that after chemotherapy, the decrease in QoL is more often related to anorexia, anemia, nausea, vomiting and asthenia, as well as other symptoms [22]. Chemotherapy has considerable effects on QoL in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life in Patients with Metastatic Breast Cancer Treated with Metronomic Chemotherapy

et al. 2016

View full text Add to dashboard Cite

Aim:The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib. Material & methods: Patients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET). Results: A total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe therapeutic profile. With FACT-B questionnaire, no significant differences were observed during the response period (BL-MT). However, a significant increase was observed in the Emotional wellbeing and Additional concerns axes, when the last time point was included in the analysis (BL-MT-ET). A significant decrease in the proportion of patients with pain was found when comparing BL with ET (p = 0.046). The assessment with Eastern Cooperative Oncologic Group scale showed that 26.7% (4/15) of the patients improved their functional status and 40% (6/15) showed no changes, while 33.3% (5/10) worsened it. Conclusion: Patients treated metronomically for several months did not worsen their QoL. A high proportion of patients showed improvement or no changes and there were less patients with pain at the end of the treatment. The quality of life (QoL) is a very common term used in different fields of human health. Therefore, it is very difficult to find a unique definition since it could be related to all aspects of human life [1].In an attempt to define it, it can be said that it is "the perfect balance between well-being and distress" [2,3]. The concept of adaptation to chronic disease is different but it is related to that of QoL; adaptation is the process whereby individuals use conscious awareness and choice to create new human environmental integration [4,5]. Both are good indicators of the evolution of psychological features of cancer patients at different stages of the disease [6]. In oncology QoL is centered in patients' health, and refers to all aspects (general, social, personal, emotional, among others) of 1234RESEaRch aRticlE Perroud, Alasino, Rico et al. future science group the subject and their relationship to the cancer disease and its treatment.The presence of pain is a very complex aspect related to QoL, and it is one of the most difficult symptoms to evaluate and to treat; in many cases pain is caused by the pressure that the tumor exerts on bones and/or nerves, and also it could be caused by cancer treatment. One of the barriers in pain treatment is the inadequate measurement and assessment of pain. An optimal management includes the evaluation of intensity, characteristics and interference with daily habits and life style [7,8].The meas...

show abstract

An evaluation of the healthcare costs associated with adverse events in patients with breast cancer

Wang

Chen

et al. 2021

Health Planning & Management

View full text Add to dashboard Cite

Objective: Despite the increasing prevalence and costs of breast cancer (BC), little is known about its adverse event (AE)-related costs in Asia. This study aimed to estimate the healthcare expenditures of AEs in patients with BC in Taiwan.Methods: This is a retrospective claims database analysis.The medical costs associated with BC AEs during the firstline treatment period were estimated by use of both a matching method and the generalized linear model (GLM).

show abstract

The Impact of Outpatient Chemotherapy-Related Adverse Events on the Quality of Life of Breast Cancer Patients

Cited by 59 publications

References 24 publications

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

Quality of Life in Patients with Metastatic Breast Cancer Treated with Metronomic Chemotherapy

An evaluation of the healthcare costs associated with adverse events in patients with breast cancer

Contact Info

Product

Resources

About